Evaluation of FDG PET in patients with cervical cancer

Journal of Nuclear Medicine

Volumn 40, Issue 7, 1999, Pages 1125-1131

  Sugawara, Yoshifumi ^a   Eisbruch, Avraham ^a   Kosuda, Shigeru ^a   Recker, Betty E ^a   Kison, Paul V ^a   Wahl, Richard L ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

18F fluoro 2 deoxy D glucose; Cervical cancer; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BLADDER; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; HUMAN; LYMPH NODE METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOISOTOPE DISTRIBUTION; RECURRENT CANCER; UTERINE CERVIX CANCER;

EID: 0033019972     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin. 1998;48:6-29.
2. Annual report on the results of treatment in gynecological cancer. Twenty-first volume. Statements of results obtained in patients treated in 1982 to 1986, inclusive 3 and 5-year survival up to 1990. Int J Gynaecol Obstet. 1991;36:1-315.
3. Eifel PJ, Berek JS, Thigpen JT. Cancer of the cervix, vagina, and vulva. In: DeVita VTJ, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. 5th ed. Philadelphia, PA: Lippincott-Raven; 1997:1433-1478.
4. Shepherd JH. Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol. 1989;96:889-892.
5. Hricak H, Yu KK. Radiology in invasive cervical cancer. AJR. 1996;167:1101-1108.
6. Yu KK, Forstner R, Hricak H. Cervical carcinoma: role of imaging. Abdom Imaging. 1997;22:208-215.
7. Stehman FB, Bundy BN, DiSaia PJ, Keys HM, Larson JE, Fowler WC. Carcinoma of the cervix treated with radiation therapy. I. A multi-variate analysis of prognostic variables in the Gynecologic Oncology Group. Cancer. 1991;67: 2776-2785.
8. Eifel PJ, Morris M, Wharton JT, Oswald MJ. The influence of tumor size and morphology on the outcome of patients with FIGO stage IB squamous cell carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys. 1994;29:9-16.
9. Creasman WT. New gynecologic cancer staging [editorial]. Gynecol Oncol. 1995;58:157-158.
10. Warburg O. The Metabolism of Tumors. New York, NY: Richard R. Smith Inc; 1931:129-169.
11. 18F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron-emission tomography. Cancer. 1991;67: 1544-1550.
12. Strauss LG, Clorius JH, Schlag P, et al. Recurrence of colorectal tumors: PET evaluation. Radiology. 1989;170:329-332.
13. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol. 1993;11:2101-2111.
14. Wahl RL, Quint LE, Greenough RL, Meyer CR, White RI, Orringer MB. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology. 1994;191:371-377.
15. Wahl RL. Positron emission tomography: application in oncology. In: Murray IPC, Ell PJ, Strauss HW, eds. Nuclear Medicine in Clinical Diagnosis and Treatment. London, England: Churchill Livingstone, Inc.; 1994;801-820.
16. Lapela M, Leskinen-Kallio S, Varpula M, et al. Imaging of uterine carcinoma by carbon-11-methionine and PET. J Nucl Med. 1994;35:1618-1623.
17. 18F]fluoro-D-glucose by direct nucleophilic exchange on a quatenary 4-aminopyridinium resin. Int J Rad Appl Instrum [B]. Nucl Med Biol. 1990;17:273-279.
18. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology. 1993;189:847-850.
19. Marshall MJ, Goldberg DM, Neal FE, Millar DR. Enzymes of glucose metabolism in carcinoma of the cervix and endometrium of the human uterus. Br J Cancer. 1978;37:990-1001.
20. Schwickert G, Walenta S, Sundfor K, Rofstad EK, Mueller-Klieser W. Correlation of high lactate levels in human cervical cancer with incidence of metastasis. Cancer Res. 1995;55:4757-4759.
21. Minn H, Joensuu H, Ahonen A, Klemi P. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer. 1988;61:1776-1781.
22. Okada J, Yoshikawa K, Itami M, et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med. 1992;33:325-329.
23. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med. 1993;34:414-419.
24. 18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest Radiol. 1987;22: 350-371.
25. Okada J, Yoshikawa K, Imazeki K, et al. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. J Nucl Med. 1991;32:686-691.
26. Ichiya Y, Kuwabara Y, Otsuka M, et al. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. J Nucl Med. 1991;32:1655-1660.
27. Spellman CM, Fottrell PF, Baynes S, O'Dwyer EM, Clinch JD. A study of some enzymes and isoenzymes of carbohydrate metabolism in human endometrium during the menstrual cycle. Clin Chim Acta. 1973;48:259-268.
28. Bhatnagar A, Shankar R, Mondai A, Chopra MK, Satija ML, Narayanan RV. Diagnosis of uterine abnormalities with radionuclide imaging. Clin Nucl Med. 1995;20:1003-1007.
29. Wahl RL, Cody RL, Fisher SJ. FDG uptake before and after estrogen receptor stimulation: feasibility studies for functional receptor imaging [abstract]. J Nucl Med. 1991;32:1011.
30. Yasuda S, Ide M, Takagi S, Shohtsu A. Intrauterine accumulation of F-18 FDG during menstruation. Clin Nucl Med. 1997;22:793-794.
31. Vinnicombe SJ, Norman AR, Nicolson V, Husband JE. Normal pelvic lymph nodes: evaluation with CT after bipedal lymphangiography. Radiology. 1995;194: 349-355.
32. Anzai Y, Carroll WR, Quint DJ, et al. Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diagnoses. Radiology. 1996;200:135-141.
33. Avril N, Dose J, Janicke F, et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Natl Cancer Inst. 1996;88:1204-1209.
34. Gritters LS, Francis IR, Zasadny KR, Wahl RL. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med. 1993;34:1420-1427.
35. Kosuda S, Kison PV, Greenough R, Grossman HB, Wahl RL. Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur J Nucl Med. 1997;24:615-620.
36. 18F]fluoro-D-glucose (FDG) activity in the urinary system. Ann Nucl Med. 1997;11:213-218.
37. Leisure GP, Vesselle HJ, Faulhaber PF, O'Donnell JK, Adler LP, Miraldi F. Technical improvements in fluorine-18-FDG PET imaging of the abdomen and pelvis. J Nucl Med Technol. 1997;25:115-119.